You are viewing an incomplete version of our website. Please click to reload the website as full version.

Interleukin 31 (IL31) (Intermediate Domain) antibody

Details for Product No. ABIN500006, Supplier: Login to see
Antigen
  • IL31
  • IL-31
  • 1700013B14Rik
Epitope
Intermediate Domain
27
13
9
8
5
5
3
3
1
1
1
1
Reactivity
Human, Mouse (Murine)
89
31
9
Host
Rabbit
97
13
1
Clonality
Polyclonal
Conjugate
Un-conjugated
14
5
4
3
3
3
3
1
1
1
1
1
1
1
1
1
Application
Enzyme Immunoassay (EIA), Western Blotting (WB)
74
64
23
18
17
15
4
3
3
2
1
1
Supplier
Login to see
Supplier Product No.
Login to see
Request

Showcase your results, aid the scientific community, and receive a full refund.

Contribute a validation

Learn more

Available images

Immunogen Human IL-31 (Intermediate Domain) Peptide
Isotype IgG
Specificity IL-31 antibody was raised against a 18 amino acid peptide from near the center of human IL-31.
Purification Affinity chromatography purified via peptide column
Alternative Name Interleukin-31 / IL31 (IL31 Antibody Abstract)
Background Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells (1,2). IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor (2). In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways (3). RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells . IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia, and skin lesions and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development (1,4).Synonyms: IL-31
Gene ID 386653
NCBI Accession NP_001014358
UniProt Q6EBC2
Pathways
Application Notes ELISA. Western Blot: 2.5 - 5 μg/mL. Despite its predicted size, IL-31 runs at approximately 27 - 30 kDa in SDS-PAGE.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Buffer PBS containing 0.02 % sodium azide.
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C
Supplier Images
Western Blotting (WB) image for anti-Interleukin 31 (IL31) (Intermediate Domain) antibody (ABIN500006) Western blot analysis of IL-31 in human skeletal muscle tissue lysate with AP30423PU-...
Background publications Bilsborough, Leung, Maurer et al.: "IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis." in: The Journal of allergy and clinical immunology, Vol. 117, Issue 2, pp. 418-25, 2006 (PubMed).

Diveu, Lak-Hal, Froger et al.: "Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling." in: European cytokine network, Vol. 15, Issue 4, pp. 291-302, 2005 (PubMed).

Dreuw, Radtke, Pflanz et al.: "Characterization of the signaling capacities of the novel gp130-like cytokine receptor." in: The Journal of biological chemistry, Vol. 279, Issue 34, pp. 36112-20, 2004 (PubMed).

Dillon, Sprecher, Hammond et al.: "Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. ..." in: Nature immunology, Vol. 5, Issue 7, pp. 752-60, 2004 (PubMed).